Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has entered into a definitive agreement with RTW Biotech Opportunities, a U.S. investment fund, for the acquisition of biotechnology firm Yellow Jersey. Yellow Jersey, a subsidiary of Swiss-based Numab, was previously acquired by RTW in 2021. The cash transaction, valued at $1.25 billion, is anticipated to be finalized in the second half of 2024.
Yellow Jersey’s pipeline features NM26, a groundbreaking first-in-class bispecific antibody (BsAb) candidate targeting atopic dermatitis, a condition characterized by chronic skin inflammation.- Flcube.com
